Hypercoagulability in obstructive sleep apnea syndrome
More details
Hide details
Medical School, Democritus University of Thrace, Alexandroupolis, Greece
Paschalis Steiropoulos   

Medical School, Democritus University of Thrace Dragana 68100, Alexandroupolis, Greece
Publication date: 2021-06-17
Pneumon 2016;29(1):22–26
Obstructive sleep apnea syndrome (OSAS) is characterized by repetitive episodes of upper airway obstruction, leading to intermittent hypoxia, hypercapnia and increased sympathetic nervous system activity and proposed to induce platelet activation. Additionally, OSAS has been linked to increased cardiovascular mortality and morbidity. Blood coagulation abnormalities have been suggested to play a fundamental role in increased cardiovascular risk in OSAS patients. The aim of the present review was to summarize the current evidence that revealed the pathogenetic alterations in blood coagulation in patients with OSAS.
Fietze I, Penzel T, Alonderis A, et al. Management of obstructive sleep apnea in Europe. Sleep Med 2011;12:190-7.
Kostapanos MS, Mikhailidis DP, Elisaf MS, Steiropoulos P, Papanas N. Obstructive sleep apnoea syndrome and cardiovascular risk. Arch Med Sci 2012;8:1115-6.
Pafili K, Steiropoulos P, Papanas N. The relationship between obstructive sleep apnoea and coronary heart disease. Curr Opin Cardiol 2015;30:439-46.
Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514- 8.
Carlson J, Hedner J, Elam M, et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993;102:1763-8.
Jennum P, Wildschiodtz G, Christensen NJ, Schwartz T. Blood pressure, catecholamines and pancreatic polypeptide in obstructive sleep apnea with and without nasal continuous positive airway pressure (nCPAP) treatment. Am J Hypertens 1989;2:847-52.
Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994;89:1951-7.
Grant JA, Scrutton MC. Novel alpha2-adrenoceptors primarily responsible for inducing platelet aggregation. Nature 1979;277:659-61.
Shattil SJ, Budzynski A, Scrutton MC. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding, and aggregation in whole blood in the absence of other excitatory agonists. Blood 1989;73:150-8.
Geiser T, Buck F, Meyer BJ, et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002;69:229-34.
Oga T, Chin K, Tabuchi A, et. al. Effects of obstructive sleep apnea with intermittent hypoxia on platelet aggregability. J Atheroscler Thromb 2009;16:862-9.
Bokinsky G, Miller M, Ault K, Husband P, Mitchell J. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure: a preliminary investigation. Chest 1995;108:625-30.
Sanner BM, Konermann M, Tepel M, et al. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000;16:648-52.
Nena E, Papanas N, Steiropoulos P, et al. Mean Platelet Volume and Platelet Distribution Width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity? Platelets 2012;23:447-54.
Dikmenoglu N, Ciftci B, Ileri E, et al. Erythrocyte deformability, plasma viscosity and oxidative status in patients with severe obstructive sleep apnea syndrome. Sleep Med 2006;7:255-61.
Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 2004;79:1036-46.
Ernst E. Fibrinogen as a cardiovascular risk factor-interrelationship with infections and inflammation. Eur Heart J 1993;14 (Suppl K):82-7.
Chin K, Ohi M, Kita H, et al. Effects of nCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996;153:1972-6.
Nobili L, Schiavi G, Bozano E, et al. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 2000;22:21-7.
Wessendorf TE, Thilmann AF, Wang YM, et al. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000;162:2039-42.
Zhang X, Yin K, Wang H, Su M, Yang Y. Effect of continuous positive airway pressure treatment on elderly Chinese patients with obstructive sleep apnea in the prothrombotic state. Chin Med J (Engl) 2003;116:1426-8.
von Känel R, Loredo JS, Ancoli-Israel S, Mills PJ, Dimsdale JE. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. Metabolism 2007;56:969-76.
Zamarrón C, Ricoy J, Riveiro A, Gude F. Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension. Lung 2008;186:151-6.
Mehra R, Xu F, Babineau DC, et al. Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study. Am J Respir Crit Care Med 2010;182:826-33.
Shitrit D, Peled N, Shitrit AB, et al. An association between oxygen desaturation and D-dimer in patients with obstructive sleep apnea syndrome. Thromb Haemost 2005;94:544-7.
von Känel R, Dimsdale JE, Ancoli-Israel S, et al. Poor sleep is associated with higher plasma proinflammatory cytokine interleukin-6 and procoagulant marker fibrin D-dimer in older caregivers of people with Alzheimer’s disease. J Am Geriatr Soc 2006;54:431-7.
Heinrich J, Balleisen L, Schulte H, Assamann G, van de Loo J. Fibrinogen and factor VII In the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-9.
Chin K, Kita H, Noguchi T, et al. Improvement of factor VII clotting activity following long-term nCPAP treatment in obstructive sleep apnoea syndrome. QJM 1998; 91:627-33.
Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004;59:777-82.
Reinhart WH, Oswald J, Walter R, Kuhn M. Blood viscosity and platelet function in patients with obstructive sleep apnea syndrome treated with nasal continuous positive airway pressure. Clin Hemorheol Microcirc 2002;27:201-7.
Steiropoulos P, Papanas N, Nena E, et al. Inflammatory markers in middle-aged obese subjects: does obstructive sleep apnea syndrome play a role? Mediators Inflamm 2010;2010:675320.
Kaditis AG, Alexopoulos EI, Kalampouka E, et al. Morning levels of fibrinogen in children with sleep disordered breathing. Eur Respir J 2004;24:790-7.
Shimizu M, Kamio K, Haida M, et al. Platelet activation in patients with obstructive sleep apnea syndrome and effects of nasal-continuous positive airway pressure. Tokai J Exp Clin Med 2002;27:107-12.
Toraldo D, Peverini F, De Benedetto M, De Nuccio F. Obstructive sleep apnea syndrome: blood viscosity, blood coagulation abnormalities, and early atherosclerosis. Lung 2013;191:1-7.
Archontogeorgis K, Nena E, Papanas N, Steiropoulos P. Biomarkers to improve diagnosis and monitoring of obstructive sleep apnea syndrome: current status and future perspectives. Pulm Med 2014;2014:930535.